These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 24603504

  • 1. Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment.
    Yeh KW, Lee CM, Chang CJ, Lin YJ, Huang JL.
    PLoS One; 2014; 9(6):e90757. PubMed ID: 24603504
    [Abstract] [Full Text] [Related]

  • 2. Association of disease activity and anti-rheumatic treatment in juvenile idiopathic arthritis with serum lipid profiles: a prospective study.
    Shen CC, Yao TC, Yeh KW, Huang JL.
    Semin Arthritis Rheum; 2013 Jun; 42(6):590-6. PubMed ID: 23290689
    [Abstract] [Full Text] [Related]

  • 3. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.
    De Sanctis S, Marcovecchio ML, Gaspari S, Del Torto M, Mohn A, Chiarelli F, Breda L.
    J Rheumatol; 2013 Jun; 40(6):943-8. PubMed ID: 23547210
    [Abstract] [Full Text] [Related]

  • 4. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, Koopman-Keemink Y, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.
    JAMA; 2011 Dec 07; 306(21):2340-7. PubMed ID: 22056397
    [Abstract] [Full Text] [Related]

  • 5. Proinflammatory cytokines in monitoring the course of disease and effectiveness of treatment with etanercept (ETN) of children with oligo- and polyarticular juvenile idiopathic arthritis (JIA).
    Kaminiarczyk-Pyzalka D, Adamczak K, Mikos H, Klimecka I, Moczko J, Niedziela M.
    Clin Lab; 2014 Dec 07; 60(9):1481-90. PubMed ID: 25291944
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
    Horneff G, Foeldvari I, Minden K, Trauzeddel R, Kümmerle-Deschner JB, Tenbrock K, Ganser G, Huppertz HI.
    Arthritis Rheumatol; 2015 May 07; 67(8):2240-9. PubMed ID: 25891010
    [Abstract] [Full Text] [Related]

  • 7. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
    Tynjälä P, Lahdenne P, Vähäsalo P, Kautiainen H, Honkanen V.
    Ann Rheum Dis; 2006 Aug 07; 65(8):1044-9. PubMed ID: 16449314
    [Abstract] [Full Text] [Related]

  • 8. Dynamics of serum levels of TNF-α in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-α biological drugs.
    Morozova N, Avramovič MZ, Markelj G, Toplak N, Avčin T.
    Clin Rheumatol; 2024 Jul 07; 43(7):2287-2293. PubMed ID: 38775868
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis.
    Windschall D, Müller T, Becker I, Horneff G.
    Clin Rheumatol; 2015 Jan 07; 34(1):61-9. PubMed ID: 25034081
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.
    Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG, Dehoorne J, Panaviene V, Susic G, Stanevica V, Kobusinska K, Zuber Z, Mouy R, Rumba-Rozenfelde I, Breda L, Dolezalova P, Job-Deslandre C, Wulffraat N, Alvarez D, Zang C, Wajdula J, Woodworth D, Vlahos B, Martini A, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO).
    Ann Rheum Dis; 2014 Jun 07; 73(6):1114-22. PubMed ID: 23696632
    [Abstract] [Full Text] [Related]

  • 11. Proteomic analysis of plasma to reveal the impact of short-term etanercept therapy in pediatric patients with enthesitis-related arthritis: a case report.
    Chen YC, Wang PW, Pan TL, Bazylak G, Shen JJ.
    Comb Chem High Throughput Screen; 2010 Jul 07; 13(6):469-81. PubMed ID: 20402637
    [Abstract] [Full Text] [Related]

  • 12. Vitamin D receptor gene polymorphism influences lipid profile in patients with juvenile idiopathic arthritis.
    Bašić J, Vojinović J, Jevtović-Stoimenov T, Despotović M, Sušić G, Lazarević D, Milošević V, Cvetković M, Pavlović D.
    Clin Rheumatol; 2019 Jan 07; 38(1):117-124. PubMed ID: 30128913
    [Abstract] [Full Text] [Related]

  • 13. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.
    Navarro-Millán I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL, Chen L, Cofield SS, Dell'Italia LJ, Moreland LW, O'Dell JR, Paulus HE, Curtis JR.
    Arthritis Rheum; 2013 Jun 07; 65(6):1430-8. PubMed ID: 23460074
    [Abstract] [Full Text] [Related]

  • 14. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.
    Aikawa NE, França IL, Ribeiro AC, Sallum AM, Bonfa E, Silva CA.
    Vaccine; 2015 Jan 29; 33(5):604-9. PubMed ID: 25554240
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM.
    Arthritis Rheum; 2003 Apr 29; 48(4):1093-101. PubMed ID: 12687553
    [Abstract] [Full Text] [Related]

  • 16. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis.
    Gudbrandsdottir S, Larsen R, Sørensen LK, Nielsen S, Hansen MB, Svenson M, Bendtzen K, Müller K.
    Clin Exp Rheumatol; 2004 Apr 29; 22(1):118-24. PubMed ID: 15005015
    [Abstract] [Full Text] [Related]

  • 17. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.
    Lahdenne P, Vähäsalo P, Honkanen V.
    Ann Rheum Dis; 2003 Mar 29; 62(3):245-7. PubMed ID: 12594111
    [Abstract] [Full Text] [Related]

  • 18. Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease.
    Donnithorne KJ, Cron RQ, Beukelman T.
    J Rheumatol; 2011 Dec 29; 38(12):2675-81. PubMed ID: 22089470
    [Abstract] [Full Text] [Related]

  • 19. Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis.
    Simonini G, Giani T, Stagi S, de Martino M, Falcini F.
    Rheumatology (Oxford); 2005 Jun 29; 44(6):777-80. PubMed ID: 15741191
    [Abstract] [Full Text] [Related]

  • 20. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis.
    Geikowski T, Becker I, Horneff G, German BIKER Registry Collaborative Study Group.
    Rheumatology (Oxford); 2014 Jul 29; 53(7):1245-9. PubMed ID: 24599916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.